Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kari Puolakka

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|April 5, 2007
[Not Available]Kari Puolakka, Marjatta Leirisalo-Repo
Duodecim; Laaketieteellinen Aikakauskirja|July 13, 2010
[The goal for the treatment of rheumatoid arthritis should be remission]Timo Möttönen, Heidi Mäkinen, Kari Puolakka
Journal of Medical Economics|November 27, 2018
Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitisTimo Purmonen, Soili Törmälehto, Hanna Wahlman, et al.
Clinical and Experimental Rheumatology|February 16, 2019
The mortality rate and causes of death among juvenile idiopathic arthritis patients in FinlandMinna Susanna Kyllönen, Hannu Kautiainen, Kari Puolakka, et al.
Cost Effectiveness and Resource Allocation : C/E|November 28, 2018
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspectiveTimo Purmonen, Kari Puolakka, Devarshi Bhattacharyya, et al.
Clinical and Experimental Rheumatology|October 18, 2012
Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritisVappu Rantalaiho, Kari Puolakka, Markku Korpela, et al.
Rheumatology (Oxford, England)|November 11, 2020
Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort studyKirsi Paalanen, Kari Puolakka, Elena Nikiphorou, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 13, 2019
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in FinlandTimo Purmonen, Kari Puolakka, Dinesh Mishra, et al.
Rheumatology (Oxford, England)|February 11, 2021
Erratum to: Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort studyKirsi Paalanen, Kari Puolakka, Elena Nikiphorou, et al.
Rheumatology Advances in Practice|May 12, 2025
Pain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritisAnna Laine, Paula Muilu, Hannu Kautiainen, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Duodecim; Laaketieteellinen Aikakauskirja|April 5, 2007
[Not Available]Kari Puolakka, Marjatta Leirisalo-Repo
Duodecim; Laaketieteellinen Aikakauskirja|July 13, 2010
[The goal for the treatment of rheumatoid arthritis should be remission]Timo Möttönen, Heidi Mäkinen, Kari Puolakka
Journal of Medical Economics|November 27, 2018
Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitisTimo Purmonen, Soili Törmälehto, Hanna Wahlman, et al.
Clinical and Experimental Rheumatology|February 16, 2019
The mortality rate and causes of death among juvenile idiopathic arthritis patients in FinlandMinna Susanna Kyllönen, Hannu Kautiainen, Kari Puolakka, et al.
Cost Effectiveness and Resource Allocation : C/E|November 28, 2018
Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspectiveTimo Purmonen, Kari Puolakka, Devarshi Bhattacharyya, et al.
Clinical and Experimental Rheumatology|October 18, 2012
Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritisVappu Rantalaiho, Kari Puolakka, Markku Korpela, et al.
Rheumatology (Oxford, England)|November 11, 2020
Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort studyKirsi Paalanen, Kari Puolakka, Elena Nikiphorou, et al.
Clinicoeconomics and Outcomes Research : CEOR|March 13, 2019
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in FinlandTimo Purmonen, Kari Puolakka, Dinesh Mishra, et al.
Rheumatology (Oxford, England)|February 11, 2021
Erratum to: Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort studyKirsi Paalanen, Kari Puolakka, Elena Nikiphorou, et al.
Rheumatology Advances in Practice|May 12, 2025
Pain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritisAnna Laine, Paula Muilu, Hannu Kautiainen, et al.
Pageof 7